Table 2.
Clinical trials with immune checkpoint inhibitors as a perioperative treatment for patients with resectable malignant pleural mesothelioma
| NCT number | Phase | No. patients | Regimens | Primary endpoints | Status |
|---|---|---|---|---|---|
| NCT03918252 | Ⅱ/Ⅲ | 30 | Arm A: preoperative Nivolumab only | Safety and feasibility | Recruiting |
| Arm B: preoperative Nivolumab + Ipilimumab | |||||
| NCT03228537 | Ⅰ | 28 | Neoadjuvant therapy with Cis‐Pem‐Atezo, surgery and maintenance with atezolizumab | Safety and feasibility | Activate |
| NCT02707666 | Ⅰ | 15 | Pembrolizumab 200 mg q3w, 3 cycles → Surgery → Cis‐Pem 4–6 cycles → Pembrolizumab 200 mg 1 year (optional) | Gamma‐interferon Gene expression profile (GEP) response rate; safety | Recruiting |
| NCT02959463 | Ⅰ | 24 | Cohort 1: Pembrolizumab 200 mg × 2 years after hemithoracic radiation therapy; Cohort 2: Pembrolizumab 200 mg × 2 years after palliative radiation therapy | Safety and feasibility | Recruiting |
| NCT02592551 | Ⅱ | 20 | Infusion of MEDI4736 (15 mg/kg intravenously, once), 1−6 weeks before surgical resection | Change in TME | Activate |
| NCT03760575 | Ⅰ | 20 | Pembrolizumab with image‐guided surgery and chemotherapy | Safety | Not yet recruiting |
| NCT04177953 | Ⅱ | 92 | Carboplatin or cisplatin and pemetrexed + nivolumab: four cycles (q4w) of a combination of platinum‐based adjuvant chemotherapy and immunotherapy | TNT and safety | Recruiting |
Abbreviations: q3w, once every 3 weeks; q4w, once every 4 weeks; TME, tumor microenvironment; TNT, time to next treatment.